Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-3: Perioperative vs adjuvant FOLFIRINOX for resectable pancreatic cancer
2024-510617-15-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of irinotecan, oxaliplatin, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Overall survival (intention-to-treat). Planned start Sep 2024; status: authorised.
02
Drugs
irinotecanoxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-510617-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510617-15-00.